BioSpace News Archive

Isofol Medical AB’s Board of Directors have, pursuant to the authorization granted by the extra general meeting on May 5, 2020, resolved on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders.

The global breast pumps market is expected to witness considerable growth over the tenure of assessment, from 2017 to 2025.

The global active pharmaceutical ingredients market was valued at US$ 162,000.0 Mn in 2017 and is projected to expand at a cumulative annual growth rate of 5.4% from 2018 to 2026, according to a new report published by Transparency Market Research titled ‘Global Active Pharmaceutical Ingredients Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2028.’

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its international expansion process.

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes.

Ascentage Pharma announced that the US Food and Drug Administration has granted HQP1351, the Company’s core drug candidate, a Fast Track Designation for the treatment of patients with chronic myeloid leukemia with certain genetic mutations who have failed to respond to treatments with existing tyrosine kinase inhibitors.

Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets close.

The company is withdrawing its previously issued fiscal year 2020 revenue and earnings per share guidance due to the COVID-19 pandemic

Endo International plc reported financial results for the first quarter ended March 31, 2020 and provided an update relating to the impact of the COVID-19 pandemic.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the first quarter ended March 31, 2020 and recent corporate updates.